APA (7th ed.) Citation

F, N., V, P., LS, Y., O, S., J, L., RMA, D., . . . G, Z. (2025). Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature medicine, 31(9), 3204. https://doi.org/10.1038/s41591-025-03895-1

Chicago Style (17th ed.) Citation

F, Nassiri, et al. "Author Correction: Oncolytic DNX-2401 Virotherapy Plus Pembrolizumab in Recurrent Glioblastoma: A Phase 1/2 Trial." Nature Medicine 31, no. 9 (2025): 3204. https://doi.org/10.1038/s41591-025-03895-1.

MLA (9th ed.) Citation

F, Nassiri, et al. "Author Correction: Oncolytic DNX-2401 Virotherapy Plus Pembrolizumab in Recurrent Glioblastoma: A Phase 1/2 Trial." Nature Medicine, vol. 31, no. 9, 2025, p. 3204, https://doi.org/10.1038/s41591-025-03895-1.